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Abstract
Background: Metastasis is the most dangerous step in cancer progression and causes more than
90% of cancer death. Although many researchers have been working on biological features and
characteristics of metastasis, most of its genetic level processes remain uncertain. Some studies
succeeded in elucidating metastasis related genes and pathways, followed by predicting prognosis
of cancer patients, but there still is a question whether the result genes or pathways contain enough
information and noise features have been controlled appropriately.
Methods: We set four tumor type classes composed of various tumor characteristics such as
tissue origin, cellular environment, and metastatic ability. We conducted a set of comparisons
among the four tumor classes followed by searching for genes that are consistently up or down
regulated through the whole comparisons.
Results:  W e  i d e n t i f i e d  f o u r  s e t s  o f  genes that are consistently differently expressed in the
comparisons, each of which denotes one of four cellular characteristics respectively – liver tissue,
colon tissue, liver viability and metastasis characteristics. We found that our candidate genes for
tissue specificity are consistent with the TiGER database. And we also found that the metastasis
candidate genes from our method were more consistent with the known biological background and
independent from other noise features.
Conclusion: We suggested a new method for identifying metastasis related genes from a large-
scale database. The proposed method attempts to minimize the influences from other factors
except metastatic ability including tissue originality and tissue viability by confining the result of
metastasis unrelated test combinations.
Background
Cancer metastasis is spread of a tumor from its primary
organ to other part or non-adjacent organs. During the
last several decades, development of cancer treatment and
surgical technology has greatly increased survival rate of
cancer patients [1], but treatment of metastasis still
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remains above of medical capability. Once cancer cells
have been disseminated to distant organs through lymph/
blood vessels, they always have a potential for re-coloni-
zation to form secondary tumors. Furthermore, the newly
generated tumors already have genuine ability to form
second metastasis [2]. From these reasons, metastasis is
the cause of about 90% of deaths from solid tumors. The
biology of metastasis has been studied for more than 100
years since Stephen Paget first proposed the 'seed and soil'
hypothesis [3]. During or after the complex genetic
changes in normal cells' tumorigenesis, a small portion of
tumor cells acquire additional abilities. It is generally
accepted that a tumor cell has to go through a lot of
obstructions and overcome harsh conditions [4,5]. For
example, the new environment hardly supplies the metas-
tasized tumor cells with hormones or ligands which are
indispensable for cellular growth and proliferation. It
means that metastasize tumor cells need to rearrange their
genetic contents to live without those signalling proteins.
Tumor cells also face with physical barriers including
basement membranes (BM), extracellular matrices (EM)
and vessel walls. In this case, some cells who secured
higher motility, ability for detachment survival and ability
to change their physical/biological characteristics through
epithelial-mesenchymal transition (EMT) get favorable
opportunities to win a competition among the other
tumor cells and move on to the next metastasis barriers.
There are many other chemical/physical barriers in whole
metastasis procedures including intravasation (getting
into a vessel), high fluid pressure in vessels, scattered
immune cells, and extravasation (getting out from a ves-
sel). Micrometastasis is a microscopic secondary tumor
resulted from a set of primary tumor cell's success in hur-
dling all of the barriers above. Forming an outgrowing
tumor in the secondary site is extremely hard because the
entire hurdling events are a series of long odds. Even
though a micrometastasis settles down in the new site, it
usually dies from the inharmonious environment sur-
rounding the cell or lies dormant due to the lack of suita-
ble growth factors. So, the metastasized tumor cells in the
secondary site have been chosen by selective pressures to
have all the abilities for metastasis [6,7]. Sometimes, these
winner cells are called 'decathlon champions'.
Many researchers have tried to explain metastatic proce-
dures in the genetic level either in small scale experiments
or from large scale expression data. Wang et al identified
76 gene signatures using 286 lymph node negative breast
cancer expression data [8]. They used unsupervised clus-
tering to classify good and bad prognosis. Tomlins et al
tried to identify gene sets which are related to prostate
cancer's progression using the 'molecular concept map'
[9]. Their result showed state related 'molecular concepts'
from normal prostate tissues to PIN (Prostate Intraepithe-
lial Neoplasia), PCA (Prostate cancer), and metastasis.
Edelman et al [10] used GSEA [11] analysis with 71 pros-
tate samples consist of 22 benign, 32 PCA, and 17 meta-
static tissues. They proposed several gene sets which are
significantly changed in the step of n → p (normal to pros-
tate cancer), and p → m (prostate cancer to metastasis). In
these genetic level studies, researchers succeeded in clearly
representing metastasis related gene sets or pathways, and
in validating their results with classification tests.
As returning to the nature of metastasis biology, however,
two substantial questions are emerging especially on the
sample comparison step. First, do the metastasis samples
really have metastasis characteristics? In Wang's work, the
samples in the metastasis class are not actually metastasis
samples; they are primary tumor samples which later turn
out to show bad prognoses. Usually in other work, the
samples used for representing metastasis are tumor sam-
ples from the very organ where the primary tumor
occurred. The only difference is that the patients where the
metastasis samples are from had metastatic tumors in
their other organs. It is seriously doubtful whether the
sample of a part of primary tumor has metastatic abilities;
maybe cells with metastatic abilities already moved out to
other organs, and only the other cells without the abilities
have remained. Second, have other metastasis independ-
ent features been eliminated in the comparison between
two samples from two distinct organs? In the case of com-
paring a sample from a primary tumor in an organ with
another sample from metastasis tumor in another organ,
there should be several elements that affect the result of
the comparisons, such as tissue specificity, tissues' envi-
ronmental viability, and a subtype of cancer. It is hardly
expected that a result gene set represents metastatic char-
acteristics only; large parts of the gene set might have been
selected for another reasons.
In this paper, we present how to alleviate the noise effects
and the lack of information in metastasis gene finding
procedures using multiple and controlled analyses. We
used a large scale expression profile database with rich
clinical information – expO [12] (expression project for
Oncology). With the clinical information, samples are cat-
egorized into several distinct sets. We investigated each set
and tagged it with its intrinsic characteristics – metastatic
ability, tissue specificity, and organ dependent viability.
Any two combinatorial sets can be chosen for further
comparisons, and the result would represent various
information depends on the differences of the selected
sets' characteristics.
Methods
We describe the data sets and scoring functions in this sec-
tion. First, the expression database and preprocess proce-
dures are explained. Second, methods for converting theBMC Bioinformatics 2009, 10(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/10/S3/S2
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probe level expression values to gene and context scores
are described.
Data preparation
Expression profile database
The expO (expression project for Oncology) database is
an archive of tumor samples with detailed clinical infor-
mation. The IGC (International Genomics Consortium)
has established a uniform system for obtaining and
processing tissue samples for molecular characterization
studies. Currently the expO database obtained 1911
tumor samples (2008-07-14) and provides the expression
data through the NCBI's public gene expression database
[13] (GEO – GSE2109 series). There are lots of clinical
attributes associated with gene expression data such as
patient's age, gender, ethnic background, tobacco use,
alcohol consumption and familial history of cancer. Fur-
thermore, cancer specific information including patho-
logical and clinical TNM stages, cancer grades, primary
tumor sites and relapse information is also available. This
standardization of both microarray platform and clinical
description greatly contributed to users conveniences.
Database construction
Although the expO database provides a lot of useful infor-
mation with great level of standardization, the large size
and the text based format (SOFT format) make it less con-
venient to analyze the data freely. To settle these prob-
lems, we constructed a relational database using the expO
contents (Figure 1, up). Firstly, we extracted clinical infor-
mation from SOFT formatted flat files using parsers. This
information was uploaded into a data table (MySQL 5.0,
Red-Hat Linux platform). The data table part was kept in
a separated storage divided into a single GSM entry. Sec-
ondly, we constructed a web-based database (developed
with JSP and JSTL) in which a user can fetch required data
using SQL query statements (Figure 1, down). Finally, we
built a program for automatic generation of input files
used in GSEA analyses (GCT and CLS files).
Experimental design
Class definition
Using the relational database and the GSEA analysis prep-
aration program, we set up four data classes of different
organ and metastatic abilities. The main concept of the
analysis describes colon cancer's metastasis to liver. The
organs, colon and liver, were selected due to the relative
sufficiency of sample numbers than those of the other
organs. The four classes are named A (a primary tumor in
liver), B (metastasis tumor in liver from a primary colon
tumor), C (a primary tumor in colon) and D (a metastasis
tumor in other organs but liver from a primary colon
tumor) respectively. Corresponding locations of four
tumor classes were depicted in Figure 2. For entry details
with clinical information, see Additional file 1.
Class A
13 samples have been assigned to class A using the below
query from expO relational database.
SELECT * FROM expo WHERE source = 'liver' AND primar-
ysite = 'liver' AND histology NOT LIKE '%metastatic%'
From the query result, the GSM203676 sample was
removed as it turned out to be a relapsed cancer. Finally,
class A has 12 primary liver tumors without any relapse
and metastasis and collected from liver.
Class B
20 samples have been assigned to class B using the below
query.
SELECT * FROM expo WHERE source = 'liver' AND primar-
ysite = 'colon' AND histology LIKE '%metastatic%'
The histology phrase ensures that the primary colon
tumor has metastasized to liver. Without the phrase, the
secondary liver cancer might be thought to be another
independent primary liver tumor after the primary colon
tumor occurred.
Class C
188 samples have been assigned to class C using the
below query.
SELECT * FROM expo WHERE source = 'colon' AND prima-
rysite = 'colon' AND histology NOT LIKE '%metastatic%'
AND pathologicalM = '0'
The pathologicalM field denotes the doctor's decision
about the tumor's metastatic aspect.
Class D
14 highly heterogeneous samples have been assigned to
the class D. We extracted 16 non-liver metastatic tumors
that are originated from colon.
SELECT * from expo WHERE primarysite = 'colon' AND
source ! = 'liver' AND source ! = 'colon' AND histology LIKE
'%metastatic'
From the 16 query results, two samples (GSM102484,
GSM137952) were removed due to the adjacency of the
metastasized organs (small intestine and peritoneum).
The remaining samples' secondary tumor sites included
ovary, lung and bladder.
Class definitionCharacteristics of each tumor class were
assessed in four criteria – metastatic ability, colon tissue
specificity, liver tissue specificity and viability in liver
environment. For example, class A has no metastatic abil-BMC Bioinformatics 2009, 10(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/10/S3/S2
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Relational and Online Database for expO Figure 1
Relational and Online Database for expO. The flat file expO database was parsed and updated into MySQL based rela-
tional database. Database schema is shown in the upper figure. Online access to the database (lower figure) is available on 
http://gto.kaist.ac.kr:8080/Expo/index.jspBMC Bioinformatics 2009, 10(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/10/S3/S2
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ity and no colon tissue specificity but it has liver tissue
specificity and liver's environmental viability, whereas
class B has metastatic ability, colon tissue specificity
(tumor has originated from colon cells) and viability in
liver's environment but no liver tissue specificity.
Differently expressed genes from two distinct classes rep-
resent characteristic gaps between those classes (see Table
1). When we compare the class A with B, the result genes
are expected to contain three kinds of characteristic differ-
ences – metastatic ability (from B), colon tissue specificity
(from B) and liver tissue specificity (from A). So, if a gene
α was up-regulated in class B, we expect that the gene α
plays a role in metastasis or colon tissue related activities.
Scoring and analysis
Differently expressed scores have been calculated based
on a t-test. A score si
AB, gene i's enrichment in class A com-
pared with class B can be obtained from the below equa-
tion.
where μ is the mean, n is the number of samples, and σ is
the standard deviation. If the si
AB score is bigger than 0, the
gene i is up-regulated in class A.
Gathering class combinations with a consistent context
gives an overview of specific characteristics. We named the
series of class combinations a context vector. For example,
a metastasis context vector of gene i is defined as below.
vmi = (si
BA, si
BC, si
DA, si
DC)
where si
BA = -si
AB, si
DA = -si
AD, si
DC = -si
CD.
Each element of the metastasis context vector denotes
how far a gene i was up-regulated in the metastatic tumor
sample in contrast to another primary tumor sample. The
bigger the each element's value, the higher dependency on
metastasis the context vector indicates. Likewise, we can
define other three context vectors – colon tissue context
vector, liver tissue context vector and liver viability context
vector.
Because we cannot jump to a conclusion that each ele-
ment belongs to a specific characteristic, we need to justify
the consistency of the element's directionality. For exam-
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Tumor class diagram Figure 2
Tumor class diagram. Each of the four classes is described 
in this figure. A is a primary tumor arisen in liver. C is a pri-
mary tumor arisen in colon. B and D are both metastatic 
tumors disseminated from primary colon tumors. Primary 
tumors are denoted by blue circles, metastatic tumors are 
denoted by red circles.
Table 1: Comparison combinations of classes and expected characteristic differences.
Comparison Tissue specificity Metastatic ability Environmental Viability
A – B O (liver VS. colon) O (only in B) X
A – C O (liver VS. colon) X (neither) O (liver only VS. colon only)
A – D O (liver VS. colon) O (only in D) O (liver only VS. anywhere but liver)
B – C X O (only in B) O (colon and liver VS. colon only)
B – D X X (both) O (colon and liver VS. anywhere but liver)
C – D X O (only in D) O (colon only VS. anywhere but liver)
'O' is marked when a certain comparison is expected to show differences in a specific context. 'X' is marked when there is no difference.BMC Bioinformatics 2009, 10(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/10/S3/S2
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ple, si
AB is used in three context values (as an si
BA form in
vmi and vli).
A high score of si
AB can be explained in one of the three
hypotheses below;
i. Gene i is down-regulated in metastatic tumors
ii. Gene i is down-regulated in colon tissues
iii. Gene i is up-regulated in liver tissues
Now, we check whether the gene i has been up or down-
regulated in other class combinations. If the si
AC, and si
AD
score were also high, all of the elements in the liver viabil-
ity context vector vli have plus values indicating that the
hypothesis iii – gene i would be up-regulated in liver tis-
sues – would be correct. We define the consistency factor
c.
The final score of gene i's dependency on a specific char-
acteristic τ is,
where vτi is a context vector of gene i on the characteristic
τ, cvτ i is a consistency factor of the vector vτi.
Results and discussion
We scored 20606 genes using the function described in
the last section. Total 54675 probe sets from an Affymetrix
U133 Plus 2.0 chip were matched to their corresponding
genes using GSEA v2 program's Collapse Dataset tool. In
the case of many to gene matching, we used the maximum
value of the probes. Enrichment scores have been calcu-
lated for six comparisons (A↔B, A↔C, A↔D, B↔C,
B↔D, C↔D), and their differently expressed genes were
denoted using six Heat Maps. The heat map of A↔B is
shown in Figure 3. Remaining heat maps are shown in
Additional file 2.
For each gene, the scores for dependency on a specific
characteristic, f(i, τ) were calculated for four τs – charac-
teristics. For example, the scores of gene HPN (hepsin,
transmembrane protease) with respect to the four charac-
teristics (metastasis, colon tissue, liver tissue, and liver via-
bility) were 0, -100.0, 100.0, and 2179 respectively, which
can be interpreted like the HPN gene is not related to
metastasis, but it is closely related to the cellular viability
in liver as Klezovitch et al has reported [14]. Top genes for
each characteristic were identified. We will discuss the top
genes and their reliability case by case.
Colon and liver tissue
As described in the section on Experimental design, the
context vector for colon is exactly the minus signed liver
context vector, because any tissues used for the sample
data were colon tissues or liver tissues, exclusively. 6691
genes from total 20606 genes scored zero (their context
vectors contain both signs of elements) in these character-
istics. RIPK3 (receptor-interacting serine-threonine kinase
3) scored highest by 1674.1 and KLHL (kelch-like 5) gene
scored lowest by -1610.9. Scores were re-scaled for more
convenient readability (multiplied power of 10s depend
on the size of context vectors). Mean score was 11.27 with
standard deviation 85.4. Top 10 genes for all characteris-
tics are shown in Table 2. We used the TiGER database
(Tissue-specific Gene Expression and Regulation) [15] to
validate the result genes' tissue specificity. In colon's case,
top 10 genes were all highly regulated in colon compared
to liver. TMPRSS4 (1442.7 colon score, 4th ranked) and
HLXB9 (Homo sapiens homeobox HB9, colon score
1125.7, 8th ranked) were registered to the TiGER colon
specific gene list. But in liver's case, no gene in the top 10
liver score list was registered to the database.
We concluded that extracted colon/liver tissue specific
genes do not contain any universal tissue specific genes.
Instead, the result includes genes relatively up or down-
regulated than in the other tissues. But this result is
enough to be used to offset any bias caused by the tissue
differences.
Liver viability
The same analysis was applied to the liver viability charac-
teristics. Mean score was 6.9 with standard deviation
513.4. Surprisingly, 9 of 10 top genes were all registered to
the TiGER's liver specific gene database (see Table 2).
Including ALB (albumin, 6216 liver viability score, 2nd
ranked), FGG (fibrinogen gamma chain, 6097 liver viabil-
ity score, 3rd ranked) and SERPINA3 (serpin peptidase
inhibitor, 5958 liver viability score, 4th ranked), all the top
genes were well known as liver specific genes. Despite
FGG and HP/HPR (Homo sapiens haptoglobin/hap-
toglobin-related protein) are significantly up-regulated in
the tissues from liver environment, their liver score were
all zero. In the case of FGG, the DEG score from A↔B was
-0.0058 making the final score 0. Similarly, HP/HPR's
zero score was due to the minus DEG score in A↔B.
The differences of two liver-related scores need to be
examined. One seeks to find any signs coming from liver
tissue's characteristics, while the other from liver's envi-
ronments. Because the liver context vector and liver viabil-
c
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ity context vector shares two elements, Si
AC and Si
AD, we
could pay attention to only Si
AB, Si
BC, and Si
BD elements. In
the result, we found Si
AB hardly catches liver specific genes.
Even though the B sample came from colon tissues, we
could see its expression pattern simulated that of liver tis-
sues. Cancer cells go through increased genetic and epige-
netic mutations, and sometimes their genetic instability
helps by providing variety and perpetuity to themselves.
During the metastasis procedures, colon cancer cells that
acquired invasion and metastasis abilities possibly
acquire activation of liver specific genes before or after
they form micrometastasis. The tissue specific gene list of
Heat map of A↔B comparison Figure 3
Heat map of A↔B comparison. Differently expressed genes were denoted in a heat map. Sample A (left cluster) is from 
primary liver tissues, sample B (right cluster) is from liver metastasis of colon cancer. As shown in Table 1, this result contains 
information of metastatic ability and tissues specificity (liver versus colon tissue). All heat maps from other comparison combi-
nations are included in Additional file 2.BMC Bioinformatics 2009, 10(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/10/S3/S2
Page 8 of 10
(page number not for citation purposes)
TiGER database has been established using EST
(Expressed Sequence Tags) tags from sample tissues. So,
the genes in the list can be identified properly not by the
tissue originality but by the activity of core genes, which
enables the cell to live in a liver. It is well shown in the
score Si
BC; even though B and C are both from colon cells,
their liver specific genes are mostly up-regulated in B. In
the mean time, we cannot stop concerning the possibility
that all the samples collected from liver tissues contain
surrounding normal liver tissues, making the entire results
more ambiguous.
Metastasis
The result shows top 10 up and down-regulated genes in
metastasis samples (Table 3, down-regulated genes are
not shown). Mean score was 5.45 with standard deviation
46.87. Unfortunately, any biological processes of top
scored gene MGC16121 (hypothetical gene, 2032 metas-
tasis score, 1st  ranked) were not discovered. PLA2R1
Table 2: Top 10 genes of four characteristics.
Characteristic Gene Score Description
Colon tissue RIPK3 1674.06 Receptor-interacting serine-threonine kinase 3
LOC146439 1664.03 -
FUT2 1463.07 Fucosyltransferase 2 (secretor status included)
TMPRSS4 1442.70 Transmembrane protease, serine 4
GJB3 1320.09 Gap junction protein, beta 3, 31 kDa (connexin 31)
C1ORF106 1248.81 Chromosome 1 open reading frame 106
USH1C 1174.67 Usher syndrome 1C (autosomal recessive, severe)
HLXB9 1125.69 Homeobox HB9
IFT172 1114.38 Intraflagellar transport 172 homolog (Chlamydomonas)
DLG3 1102.68 Discs, large homolog 3 (neuroendocrine-dlg, Drosophila)
Liver tissue KHLH5 1610.92 Kelch-like 5
TUBB2A 1185.24 Tubulin, beta 2A
QKI 1100.99 Quaking homolog, KH domain RNA binding
FAM107B 798.17 Family with sequence similarity 107, member B
RAB7L1 765.74 RAB7, member RAS oncogene family-like 1
GTF2H2 716.89 -
CAP2 708.44 CAP, adenylate cyclase-associated protein 2
IL6ST 706.20 Interleukin 6 signal transducer
PTPLB 702.20 Protein tyrosin phosphatase-like B
CPEB4 635.24 Cytoplasmic polyadenylation elemenet binding protein
Liver viability C4A 6614.23 Complement component 4A (Rodgers blood group)
ALB 6216.49 Albumin
FGG 6096.9 Fibrinogen gamma chain
SERPINA3 5958.13 Serpin peptidase inhibitor, clade A
FGA 5641.41 Fibrinogen alpha chain
HP 5634.32 Haptoglobin
LAMP2 5549.98 Lysosomal-associated membrane protein2
FGB 5446.63 Fibrinogen beta chain
AGT 5353.17 Angiotensinogen
APOA2 5343.06 Apolipoprotein A-II
Metastasis MGC16121 2032.63 -
PLA2R1 1405.16 Phospholipase A2 receptor1, 180 kDa
TREM2 812.81 Triggering receptor expressed on myeloid cells 2
HS3ST2 647.47 Heparin sulfate 3-O-sulfotransferase 2
ST6GAL2 627.44 ST6 beta-galactosamide alpha-2,6-sialytransferase 2
ATP10A 584.84 ATPase, class V, type 10A
BGN 563.69 Biglycan
RAB11FIP3 546.31 RAB11 family interacting protein 3
RAD51L1 510.23 RAD51-like 1
C20ORF12 483.49 Chromosome 20 open reading frame 12
All genes are ranked by the final characteristic score. Functionally unknown genes or hypothetical genes are denoted by '-' in their description 
columns.BMC Bioinformatics 2009, 10(Suppl 3):S2 http://www.biomedcentral.com/1471-2105/10/S3/S2
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(phospholipase A2 receptor 1, 1405 metastasis score, 2nd
ranked) is known to acts as a receptor for phospholipase
sPLA2-IB and also bind to snake PA2-like toxins. Binding
of sPLA2-IB induces various effects [16] including activa-
tion of MAPK cascade to induce cell proliferation and
inflammatory reactions which are well known metastasis
procedures by increasing cellular motility and angiogen-
esis [17,18]. TREM2 (triggering receptor expressed on
myeloid cells 2, 1405 metastasis score, 3rd ranked) is also
known to have a role in chronic inflammations and stim-
ulate production of constitutive chemokines and
cytokines [19]. On the other hands, PTPLB (protein tyro-
sine phosphatase-like member b, -1189 metastasis score,
top down-regulated) is significantly down-regulated in all
metastasis samples. The main function of PTPLB is not
well discovered so that the direct relation to metastasis is
hard to find. But PTPLB is known to interact with BAP31
[20] which is involved in CASP8-mediated apoptosis [21]
which is an important pathway in tumorigenesis and
metastasis resistance [22].
To prove the enhancement of the result we compared two
gene lists from B↔C and post-processed B↔C with our
method. B↔C (liver metastasis of colon cancer versus pri-
mary colon cancer) is a commonly used comparison for
extracting metastatic signatures. As shown in the Table 3,
a result from B↔C also contains liver viability characteris-
tics as well as metastasis characteristics. So we normalized
both of the B↔C and liver viability scores and found gene
sets whose B↔C scores are high but liver viability scores
are low. Because the liver viability context vector already
contains Si
BC, we modified the context vector removing
the element. As we expected, the Pearson correlation of
two scores was 0.469 indicating that large parts of B↔C
comparison result is due to the liver viability characteris-
tics. As shown in Table 3, almost half of the top scored
genes merely from the B↔C comparison were liver spe-
cific genes. But there was no liver specific gene in the top
20 gene list in modified results. All the top 10 genes
including COLEC11 (collectin sub-family member 11),
FGG (fibrinogen gamma chain), ART4 (ADP-ribosyltrans-
ferase 4), ALB (albumin), and HP (haptoglobin) were
removed in the modified result. Instead, metastasis candi-
date genes including AOAH [23] (acyloxyacyl hydrolase),
EPO [24] (erythropoietin) and MAR1 (macrophage scav-
enger receptor1, involved in inflammation pathways)
were newly included. We are expecting the other genes
would be validated further.
Conclusion
We suggested a new method for identifying metastasis
related genes from a large scale database. The proposed
method attempts to minimize the influences from other
factors but metastasis including tissue originality and tis-
sue viability by confining the result of metastasis unre-
lated test combinations. We presented tissue specific and
tissue viability related genes, and validated them using tis-
sue specificity database, TiGER. Finally, we presented
Table 3: B↔C comparison and modified result.
Class Gene B vs. C Liver viability Difference Liver and metastasis dependency
B↔C only COLEC11 3.95 2.45 1.49 Liver up-regulated
NRBP2 3.29 3.57 -0.28 Liver up-regulated
FGG 3.26 3.81 -0.55 Liver specific
ART4 3.19 2.08 1.10 Liver specific
LBP 3.15 3.44 -0.28 -
GADD45B 3.15 2.82 0.33 -
HP /// HPR 3.11 3.69 -0.58 Liver specific
ALB 3.088 3.80 -0.71 Liver specific
C10ORF11 3.06 2.25 0.80 -
GCKR 3.03 3.40 -0.36 -
Modified with liver viability MGC16121 2.43 -1.39 3.83 Unknown
HS3ST2 2.34 -0.39 2.74 -
DHRS12 2.11 -0.43 2.54 -
MSR1 2.07 -0.33 2.41 Inflammation
DNASE1 2.10 -0.23 2.33 -
MARCO 2.86 0.55 2.31 Macrophage receptor
SPAG4 2.18 -0.10 2.28 -
INMT 2.93 0.71 2.22 -
AOAH 2.45 0.26 2.19 Metastasis related
EPO 2.20 0.14 2.05 Cancer and metastasis
The result of a naive comparison between a metastatic tumor (B) and a primary tumor (C) is shown in the upper row. This comparison is expected 
to represent not only metastatic ability but also liver environmental viability. Normalizing with the liver environmental viability related genes 
successfully eliminated many genes not selected for metastatic characteristics in the result of our methods (lower row).Publish with BioMed Central    and   every 
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metastasis candidate genes by calculating differences of
metastasis and liver viability normalized scores. We
would like to expand the experiments to other tissues
using remaining records of the databases and further vali-
date the result by constructing classifiers.
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